Free Trial
→ Here’s Why Trump Won’t End The Iran War (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$276.24
+1.4%		$259.06
$190.75
▼
$277.60
$488.47B0.244.53 million shs4.30 million shs
Incyte Corporation stock logo
INCY
Incyte
$112.79
+0.0%		$122.76
$82.82
▼
$132.60
$22.86B0.741.75 million shs1.12 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$225.00
+14.2%		$140.07
$22.28
▼
$225.00
$89.83B1.0916.98 million shs28.85 million shs
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$746.54
+0.9%		$790.99
$541.00
▼
$859.34
$76.86B0.16763,814 shs466,017 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
+1.48%+4.93%+10.04%+11.39%+19.45%
Incyte Corporation stock logo
INCY
Incyte
+0.04%-2.18%-10.49%-3.36%+32.10%
Moderna, Inc. stock logo
MRNA
Moderna
+14.21%+18.41%+65.92%+229.57%+705.87%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
+0.94%+1.54%-7.57%+12.34%+32.40%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$276.24
+1.4%		$259.06
$190.75
▼
$277.60
$488.47B0.244.53 million shs4.30 million shs
Incyte Corporation stock logo
INCY
Incyte
$112.79
+0.0%		$122.76
$82.82
▼
$132.60
$22.86B0.741.75 million shs1.12 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$225.00
+14.2%		$140.07
$22.28
▼
$225.00
$89.83B1.0916.98 million shs28.85 million shs
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$746.54
+0.9%		$790.99
$541.00
▼
$859.34
$76.86B0.16763,814 shs466,017 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
+1.48%+4.93%+10.04%+11.39%+19.45%
Incyte Corporation stock logo
INCY
Incyte
+0.04%-2.18%-10.49%-3.36%+32.10%
Moderna, Inc. stock logo
MRNA
Moderna
+14.21%+18.41%+65.92%+229.57%+705.87%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
+0.94%+1.54%-7.57%+12.34%+32.40%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbbVie Inc. stock logo
ABBV
AbbVie
2.83
Moderate Buy$277.180.34% Upside
Incyte Corporation stock logo
INCY
Incyte
2.52
Moderate Buy$127.7013.22% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.08
Hold$78.17-65.26% Downside
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
2.74
Moderate Buy$834.2411.75% Upside

Current Analyst Ratings Breakdown

Latest INCY, ABBV, MRNA, and REGN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/9/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$288.00
10/8/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeBuy (B-) ➝ Buy (B)
10/8/2026
Incyte Corporation stock logo
INCY
Incyte
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeBuy (B) ➝ Buy (B+)
10/8/2026
Incyte Corporation stock logo
INCY
Incyte
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetSector Perform$109.00 ➝ $114.00
10/8/2026
AbbVie Inc. stock logo
ABBV
AbbVie
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$285.00 ➝ $300.00
10/8/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$285.00 ➝ $290.00
10/8/2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetSector Perform$737.00 ➝ $810.00
10/7/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$296.00 ➝ $310.00
10/7/2026
Moderna, Inc. stock logo
MRNA
Moderna
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetEqual Weight$89.00 ➝ $95.00
10/7/2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$772.00 ➝ $780.00
10/7/2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetEqual Weight$758.00 ➝ $779.00
(Data available from 10/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbbVie Inc. stock logo
ABBV
AbbVie
$61.16B7.98$15.14 per share18.25($1.83) per share-150.95
Incyte Corporation stock logo
INCY
Incyte
$5.14B4.45$6.18 per share18.25$26.32 per share4.29
Moderna, Inc. stock logo
MRNA
Moderna
$1.94B46.21N/AN/A$22.14 per share10.16
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$14.34B5.36$41.99 per share17.78$295.66 per share2.52
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbbVie Inc. stock logo
ABBV
AbbVie
$4.23B$3.5478.0317.221.269.80%-422.07%14.34%10/30/2026 (Estimated)
Incyte Corporation stock logo
INCY
Incyte
$1.29B$7.8514.3714.803.6027.71%29.93%22.88%10/29/2026 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$2.82B-$7.99N/AN/AN/A-141.43%-28.30%-19.39%11/5/2026 (Estimated)
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$4.50B$40.4618.4514.111.4027.86%13.47%10.34%10/30/2026 (Estimated)

Latest INCY, ABBV, MRNA, and REGN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$1.10N/AN/AN/A$892.40 millionN/A
10/30/2026Q3 2026
AbbVie Inc. stock logo
ABBV
AbbVie
$3.83N/AN/AN/A$17.32 billionN/A
10/30/2026Q3 2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$16.03N/AN/AN/A$4.54 billionN/A
10/29/2026Q3 2026
Incyte Corporation stock logo
INCY
Incyte
-$3.20N/AN/AN/A$1.47 billionN/A
7/31/2026Q2 2026
AbbVie Inc. stock logo
ABBV
AbbVie
$3.61$3.65+$0.04$2.03$16.80 billion$16.99 billion
7/31/2026Q2 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$2.03-$1.97+$0.06-$1.97$102.93 million$145.00 million
7/30/2026Q2 2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$10.16$14.29+$4.13$12.23$3.82 billion$4.29 billion
7/28/2026Q2 2026
Incyte Corporation stock logo
INCY
Incyte
$2.15$3.09+$0.94$2.81$1.50 billion$1.67 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AbbVie Inc. stock logo
ABBV
AbbVie
$6.922.51%+6.80%195.48%53 Years
Incyte Corporation stock logo
INCY
Incyte
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$3.760.50%N/A9.29%N/A

Latest INCY, ABBV, MRNA, and REGN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
9/10/2026
AbbVie Inc. stock logo
ABBV
AbbVie
quarterly$1.732.71%10/15/202610/15/202611/16/2026
7/30/2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
quarterly$0.940.46%8/18/20268/18/20268/31/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbbVie Inc. stock logo
ABBV
AbbVie
N/A
0.81
0.69
Incyte Corporation stock logo
INCY
Incyte
N/A
4.59
4.51
Moderna, Inc. stock logo
MRNA
Moderna
0.09
2.29
2.18
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
0.06
3.34
2.78

Institutional Ownership

CompanyInstitutional Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
70.23%
Incyte Corporation stock logo
INCY
Incyte
96.97%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
83.31%

Insider Ownership

CompanyInsider Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
0.06%
Incyte Corporation stock logo
INCY
Incyte
16.20%
Moderna, Inc. stock logo
MRNA
Moderna
10.80%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
6.97%
CompanyEmployeesShares OutstandingFree FloatOptionable
AbbVie Inc. stock logo
ABBV
AbbVie
57,0001.77 billion1.77 billionOptionable
Incyte Corporation stock logo
INCY
Incyte
2,844202.70 million169.86 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
4,700399.24 million356.12 millionOptionable
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
15,410102.96 million95.78 millionOptionable

Recent News About These Companies

Royal Bank Of Canada Forecasts Strong Price Appreciation for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock
October 10 at 3:18 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31105232
Why Regeneron (REGN) is a Top Value Stock for the Long-Term
October 9 at 10:41 AM  |  zacks.comhttps://www.zacks.com/stock/news/3003752/why-regeneron-regn-is-a-top-value-stock-for-the-long-term?cid=cs-stocknewsapi-ft-fundamental_analysis|zacks_education_value_score-3003752
Morgan Stanley Forecasts Strong Price Appreciation for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock
October 9 at 2:42 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31101838
What Is Going On With Regeneron Stock?
October 8 at 8:36 PM  |  trefis.comT
Regeneron Advances Pediatric Rare Disease Program With New Phase 3 Garetosmab Study
October 8 at 12:50 PM  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/regeneron-advances-pediatric-rare-disease-program-with-new-phase-3-garetosmab-study?utm_source=marketbeat.com&utm_medium=referral
Royal Bank Of Canada Issues Positive Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price
October 8 at 10:12 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-royal-bank-of-canada-issues-positive-forecast-for-regeneron-pharmaceuticals-nasdaq-regn-stock-price-2026-10-08/
Is Biohaven (BHVN) Quietly Recasting Its Oncology Strategy Through Deeper Ties With Regeneron?
October 8 at 9:22 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/biohaven-bhvn-quietly-recasting-oncology-061804100.html
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Gets Price Target Bump from Truist Financial
October 7 at 1:29 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-regeneron-pharmaceuticals-nasdaq-regn-stock-gets-price-target-bump-from-truist-financial-2026-10-07/
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Expected to Rise, Morgan Stanley Analyst Says
October 7 at 11:17 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-regeneron-pharmaceuticals-nasdaq-regn-stock-price-expected-to-rise-morgan-stanley-analyst-says-2026-10-07/
Analysts Conflicted on These Healthcare Names: Regeneron (REGN) and NeoGenomics (NEO)
October 7 at 9:10 AM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/REGN/pressreleases/5002595/analysts-conflicted-on-these-healthcare-names-regeneron-regn-and-neogenomics-neo/
Expanded Sanofi Alliance And New Pipeline Data Could Be A Game Changer For Regeneron (REGN)
October 6, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/expanded-sanofi-alliance-pipeline-data-220928222.html
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Medtronic (MDT) and Regeneron (REGN)
October 6, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/REGN/pressreleases/4981544/analysts-opinions-are-mixed-on-these-healthcare-stocks-medtronic-mdt-and-regeneron-regn/
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $950.00
October 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31092330
Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $950.00 Price Target at JPMorgan Chase & Co.
October 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-regeneron-pharmaceuticals-nasdaq-regn-given-new-95000-price-target-at-jpmorgan-chase-co-2026-10-06/
Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026
October 6, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/regeneron-showcases-advances-care-across-110000480.html
Regeneron (NASDAQ: REGN) signs $1.0 billion Sanofi pact for new antibodies
October 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31091894
Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026
October 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/06/3375301/0/en/regeneron-showcases-advances-in-care-across-several-cancers-and-cancer-associated-complications-at-esmo-2026.html
Regeneron: The Easy Money Has Been Made (Rating Downgrade)
October 4, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4951833-regeneron-easy-money-made-rating-downgrade
Barclays Sticks to Its Buy Rating for Regeneron (REGN)
October 4, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/REGN-Q/pressreleases/4941549/barclays-sticks-to-its-buy-rating-for-regeneron-regn/
Robert W. Baird Sticks to Their Hold Rating for Regeneron (REGN)
October 4, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/REGN/pressreleases/4943748/robert-w-baird-sticks-to-their-hold-rating-for-regeneron-regn/
Argus Research upgrades Regeneron Pharmaceuticals to buy from hold
October 4, 2026  |  msn.comhttps://www.msn.com/en-us/money/other/argus-research-upgrades-regeneron-pharmaceuticals-to-buy-from-hold/ar-AA2dtYsq

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Micron, Coherent and Tower Semiconductor: 3 Stocks Built on AI's Bottlenecks
NVIDIA Just Named AI's Next Bottleneck—And These 3 Stocks Sit Right In It
By Bridget Bennett | September 20, 2026
Stacks of coins rising on a desk beside a computer with an upward stock chart, with a blurred city skyline behind.
3 Dividend Kings to Buy While They’re Still Beaten Down
By Thomas Hughes | September 14, 2026
Shopping bags sit on a polished marble floor inside an upscale retail store or shopping mall.
3 Luxury Consumer Brands to Watch in a Beaten-Down Sector
By Nathan Reiff | September 16, 2026
Computer monitor with a red plunging chart arrow on a desk, symbolizing software stocks selloff amid AI fears.
MarketBeat's Most Downgraded Stocks in Q3: 2 Look Cheap, 1 Looks Risky
By Thomas Hughes | September 15, 2026
Laboratory workbench with chromatography instrument, pipettes, sample vials, and a notebook, with a production line visible beyond the glass wall.
3 Healthcare Dividend Stocks Offering More Than Just Income
By Chris Markoch | September 30, 2026
AbbVie stock logo

AbbVie NYSE:ABBV

$276.24 +3.82 (+1.40%)
Closing price 10/9/2026 03:59 PM Eastern
Extended Trading
$276.25 +0.01 (+0.00%)
As of 10/9/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Incyte stock logo

Incyte NASDAQ:INCY

$112.79 +0.04 (+0.04%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$113.30 +0.50 (+0.45%)
As of 10/9/2026 07:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Moderna stock logo

Moderna NASDAQ:MRNA

$225.00 +28.00 (+14.21%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$225.45 +0.45 (+0.20%)
As of 10/9/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Regeneron Pharmaceuticals stock logo

Regeneron Pharmaceuticals NASDAQ:REGN

$746.54 +6.97 (+0.94%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$746.75 +0.21 (+0.03%)
As of 10/9/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas